NURIX THERAPEUTICS, INC. Operating Lease, Payments
NURIX THERAPEUTICS, INC. (NRIX) reported Operating Lease, Payments of $2.33 million for the 6-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. operating lease, payments for the quarter ending 2026-05-31 was $1.55M, a 28.75% decline year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, payments for the quarter ending 2026-02-28 was $775.00K, a 63.97% decline year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, payments for the quarter ending 2025-11-30 was $1.71M, a 20.39% decline year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, payments for the quarter ending 2025-08-31 was $2.20M, a 2.90% increase year-over-year.
- NURIX THERAPEUTICS, INC. operating lease, payments for fiscal 2025 was $8.24M, a 0.96% decline from fiscal 2024.
- NURIX THERAPEUTICS, INC. operating lease, payments for fiscal 2024 was $8.32M, a 19.32% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. operating lease, payments for fiscal 2023 was $6.97M, a 6.00% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. operating lease, payments for fiscal 2022 was $6.58M, a 63.39% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2026-05-31 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $2.33M 10-Q · filed 2026-07-09 | $4.04M derived: sum of 3 quarters · filed 2026-07-09 | $6.24M derived: sum of 4 quarters · filed 2026-07-09 | |
| 2026-02-28 | $775.00K 10-Q · filed 2026-04-08 | $2.48M derived: sum of 2 quarters · filed 2026-04-08 | $4.68M derived: sum of 3 quarters · filed 2026-04-08 | $6.86M derived: sum of 4 quarters · filed 2026-07-09 | |
| 2025-11-30 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $3.91M derived: sum of 2 quarters · filed 2026-01-28 | $6.09M derived: sum of 3 quarters · filed 2026-07-09 | $8.24M 10-K · filed 2026-01-28 | |
| 2025-08-31 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $4.38M derived: sum of 2 quarters · filed 2026-07-09 | $6.53M 10-Q · filed 2025-10-09 | $8.68M derived: sum of 4 quarters · filed 2026-07-09 | |
| 2025-05-31 | $2.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-09 | $4.33M 10-Q · filed 2026-07-09 | $6.47M derived: sum of 3 quarters · filed 2026-07-09 | $8.62M derived: sum of 4 quarters · filed 2026-07-09 | |
| 2025-02-28 | $2.15M 10-Q · filed 2026-04-08 | $4.29M derived: sum of 2 quarters · filed 2026-04-08 | $6.43M derived: sum of 3 quarters · filed 2026-04-08 | $8.55M derived: sum of 4 quarters · filed 2026-04-08 | |
| 2024-11-30 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $4.28M derived: sum of 2 quarters · filed 2026-01-28 | $6.40M derived: sum of 3 quarters · filed 2026-01-28 | $8.32M 10-K · filed 2026-01-28 | |
| 2024-08-31 | $2.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-09 | $4.26M derived: sum of 2 quarters · filed 2025-10-09 | $6.18M 10-Q · filed 2025-10-09 | $8.97M derived: sum of 4 quarters · filed 2026-01-28 | |
| 2024-05-31 | $2.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-09 | $4.04M 10-Q · filed 2025-07-09 | $6.83M derived: sum of 3 quarters · filed 2026-01-28 | $8.23M derived: sum of 4 quarters · filed 2026-01-28 | |
| 2024-02-29 | $1.92M 10-Q · filed 2025-04-08 | $4.71M derived: sum of 2 quarters · filed 2026-01-28 | $6.11M derived: sum of 3 quarters · filed 2026-01-28 | $7.50M derived: sum of 4 quarters · filed 2026-01-28 | |
| 2023-11-30 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $4.20M derived: sum of 2 quarters · filed 2026-01-28 | $5.58M derived: sum of 3 quarters · filed 2026-01-28 | $6.97M 10-K · filed 2026-01-28 | |
| 2023-08-31 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-11 | $2.79M derived: sum of 2 quarters · filed 2024-10-11 | $4.18M 10-Q · filed 2024-10-11 | $5.56M derived: sum of 4 quarters · filed 2025-01-28 | |
| 2023-05-31 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-11 | $2.78M 10-Q · filed 2024-07-11 | $4.16M derived: sum of 3 quarters · filed 2025-01-28 | $5.79M derived: sum of 4 quarters · filed 2025-01-28 | |
| 2023-02-28 | $1.39M 10-Q · filed 2024-04-10 | $2.77M derived: sum of 2 quarters · filed 2025-01-28 | $4.40M derived: sum of 3 quarters · filed 2025-01-28 | $6.65M derived: sum of 4 quarters · filed 2025-01-28 | |
| 2022-11-30 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $3.01M derived: sum of 2 quarters · filed 2025-01-28 | $5.26M derived: sum of 3 quarters · filed 2025-01-28 | $6.58M 10-K · filed 2025-01-28 | |
| 2022-08-31 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-12 | $3.88M derived: sum of 2 quarters · filed 2023-10-12 | $5.20M 10-Q · filed 2023-10-12 | $6.44M derived: sum of 4 quarters · filed 2023-10-12 | |
| 2022-05-31 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-13 | $3.56M 10-Q · filed 2023-07-13 | $4.81M derived: sum of 3 quarters · filed 2023-07-13 | $5.80M derived: sum of 4 quarters · filed 2023-07-13 | |
| 2022-02-28 | $1.32M 10-Q · filed 2023-04-13 | $2.56M derived: sum of 2 quarters · filed 2023-04-13 | $3.55M derived: sum of 3 quarters · filed 2023-04-13 | $4.50M derived: sum of 4 quarters · filed 2023-04-13 | |
| 2021-11-30 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $2.23M derived: sum of 2 quarters · filed 2023-02-09 | $3.18M derived: sum of 3 quarters · filed 2023-02-09 | $4.03M 10-K · filed 2023-02-09 | $4.00M 10-K · filed 2022-01-28 |
| 2021-08-31 | $992.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | $1.94M derived: sum of 2 quarters · filed 2022-10-06 | $2.78M 10-Q · filed 2022-10-06 | ||
| 2021-05-31 | $946.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | $1.79M 10-Q · filed 2022-07-07 | |||
| 2021-02-28 | $846.00K 10-Q · filed 2022-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |